Table 1.
Demographic data of seventy post-bariatric surgery patients; overall and according to weight loss status
| Total patients (N = 70) | Non-successful weight loss patients (N = 24, 34.3%) | Successful weight loss patients (N = 46, 65.7%) | |
|---|---|---|---|
| Mean age (SD) | 41 (9.6) | 40 (8.7) | 42 (10) |
| Sex | |||
| Male (%) | 24 (34.3%) | 11 (45.8%) | 13 (28.3%) |
| Female (%) | 46 (65.7%) | 13 (54.2%) | 33 (71.7%) |
| Bariatric surgery | |||
| RYGBa | 48 (68.6%) | 17 (70.8%) | 31 (67.4%) |
| SGa | 22 (31.4%) | 7 (29.2%) | 15 (32.6%) |
| Mean (SD) months after surgery | 14.5 (20) | 9.98 (14.8) | 18 (20.8) |
| Mean (SD) preoperative weight | 131.38 (29.85) | 137.22 (28.82) | 128.33 (30.24) |
| Mean (SD) preoperative BMI | 43.38 (9.68) | 50.17 (9.54) | 47.44 (9.73) |
| Mean (SD) current weight | 94.83 (23.9) | 114.7 (24.88) | 84.47 (15.46) |
| Mean (SD) current BMIa | 34.9 (8.14) | 42 (8.43) | 31.3 (5.03) |
| Mean (SD) total weight reduction percentage | 27.31 (27.37) | 16.2 (6.95) | 33.11 (7.81) |
| Mean (SD) EBWLa percentage | 60.7 (26.2) | 32.9 (13) | 75.2 (18.4) |
| Diet modification | |||
| Yes (%) | 59 (84.3%) | 21 (87.5%) | 38 (82.6%) |
| No (%) | 11 (15.7%) | 3 (12.5%) | 8 (17.4%) |
| Underlying diseases | |||
| Hypertension, n (%) | 42 (60%) | 15 (62.5%) | 27 (58.7%) |
| Dyslipidemia, n (%) | 38 (54.3%) | 16 (66.7%) | 22 (47.8%) |
| Diabetes, n (%) | 37 (52.9%) | 15 (62.5%) | 22 (47.8%) |
| PCOSa, n (%) | 19 (27.1%) | 5 (20.8%) | 14 (30.4%) |
| Othersb, n (%) | 100 (142.9%) | 37 (154.7%) | 74 (158.7%) |
aBMI body mass index, EBWL percentage excess body weight loss percentage, calculated by [(pre-operative BMI – follow-up BMI)/ (pre-operative BMI – Ideal Body Weight (IBW))] × 100. Ideal body weight was based on a BMI of 25 kg/m2, RYGB Roux-en-Y gastric bypass, PCOS polycystic ovarian syndrome, SG sleeve gastrectomy; (kg/m2)
bOthers underlying diseases are referred to coronary artery diseases, obstructive sleep apnea (OSA), non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD), kidney disease, inflammatory diseases, hypothyroidism, malignancy, hyperuricemia